Kiromic BioPharma Inc Ordinary Shares KRBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KRBP is a good fit for your portfolio.
News
-
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
-
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
-
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
-
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
-
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
-
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
-
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
-
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
Trading Information
- Previous Close Price
- $2.71
- Day Range
- $2.38–3.08
- 52-Week Range
- $0.16–8.97
- Bid/Ask
- $2.25 / $3.60
- Market Cap
- $3.97 Mil
- Volume/Avg
- 1,450 / 6,464
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 35
- Website
- https://www.kiromic.com
Valuation
|
Metric
|
KRBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KRBP
|
|---|---|
Quick Ratio | 0.16 |
Current Ratio | 0.22 |
Interest Coverage | −10.31 |
Quick Ratio
KRBP
Profitability
|
Metric
|
KRBP
|
|---|---|
Return on Assets (Normalized) | −146.50% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −350.73% |
Return on Assets
KRBP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zxsygzttt | Hgpk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vdqrgrylg | Kqfdjnn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Swwmqyhrd | Rwyprq | $97.8 Bil | |
MRNA
| Moderna Inc | Fzbvksfcl | Xqd | $41.3 Bil | |
ARGX
| argenx SE ADR | Jxfqqrg | Jbxrq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jbsfnwbvz | Fjbjn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nhkyvnvd | Tthlqrz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cnbgxnjk | Dnfndx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vfqpqxlnwd | Kmxddm | $12.5 Bil | |
INCY
| Incyte Corp | Gvftxddbx | Qjtgjnd | $11.6 Bil |